Triplet Regimen for Microsatellite Stable, BRAF V600E–Mutant mCRC Aims to Build Upon SOCFebruary 27th 2023
Because a positive correlation has been shown between expression of PD-L1 and BRAF V600E mutations in CRC, several combination therapies with checkpoint inhibitors and targeted agents are currently being explored.
Finding and Leveraging CEACAM5 Presents Opportunities and PitfallsFebruary 24th 2023
As carcinoembryonic antigen–related cell adhesion molecule 5 continues to show promise a target in patients with non–small cell lung cancer, refinements in testing and the understanding of the implications of its inhibition remain under investigation.
The Implications of the Underappreciated, Evolving View of Cancer as a Chronic IllnessFebruary 21st 2023
Successful manipulation of the immune system to achieve regression of cancer, long an unfulfilled goal of oncologic investigation, is an ever-increasing reality in multiple clinical settings.